ArticleBMC psychiatry2025
Cognitive dysfunction in schizophrenia: association with peripheral blood inflammatory signatures.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence-based diagnostic model for schizophrenia in individuals living with HIV.Frontiers in psychiatry · 2026Article
- Peripheral immune and kynurenine profiles are associated with cognitive change during early treatment of first-episode schizophrenia.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSchizophrenia (SCZ) is a complex, chronic neuropsychiatric disorder involving genetic, neurotransmitter, and immune system interactions. The immune-inflammatory hypothesis has emerged as a key research focus, with evidence suggesting that aberrant peripheral inflammatory factors may cross the blood-brain barrier, contributing to neurodegeneration and cognitive impairment. However, most studies have focused on single or a few inflammatory factors, with heterogeneous results, and their clinical utility as biomarkers remains unclear. This study aims to identify differentially expressed inflammatory factors in the peripheral blood of SCZ patients undergoing olanzapine treatment, evaluate their diagnostic efficacy using multidimensional statistical modeling, and investigate correlations with positive/negative symptoms and cognitive function, providing new insights into immune-inflammatory mechanisms.
methodsWe recruited 40 SCZ patients on monotherapy with olanzapine as the study group and 40 individuals without a psychiatric history as the healthy control group, collecting their blood samples and basic demographic data. The levels of inflammatory factors were measured using a flow cytometric immunoassay with fluorescently encoded microspheres. Symptom severity was assessed using the PANSS, and cognitive function was evaluated using the MCCB.
resultsCompared to healthy controls, SCZ showed significantly elevated Eotaxin and MCP1 levels and cognitive deficits across all MCCB cognitive domains. LASSO regression and Boruta algorithm identified Eotaxin and MCP1 as key predictors. Although these biomarkers were not associated with PANSS scores (p > 0.05), Eotaxin showed negative correlations with all MCCB subdomains (p < 0.05), while MCP1 correlated negatively with processing speed (p = 0.042) and attention/vigilance (p = 0.017). The final model demonstrated good discrimination (AUC = 0.838, 95% CI: 0.750-0.825) and calibration (p = 0.8958).
conclusionEotaxin may clarify cognitive impairments in SCZ patients, while MCP1 mainly focuses on the aspects of attention/vigilance as evaluated by the MCCB. Eotaxin and MCP1 are potential biomarkers for SCZ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.